Cargando…
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
Rationale: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be efficacious and safe in patients ≥12 years of age with cystic fibrosis and at least one F508del-CFTR (cystic fibrosis transmembrane conductance regulator) allele, but it has not been evaluated in children <12 years of age....
Autores principales: | Zemanick, Edith T., Taylor-Cousar, Jennifer L., Davies, Jane, Gibson, Ronald L., Mall, Marcus A., McKone, Edward F., McNally, Paul, Ramsey, Bonnie W., Rayment, Jonathan H., Rowe, Steven M., Tullis, Elizabeth, Ahluwalia, Neil, Chu, Chenghao, Ho, Thang, Moskowitz, Samuel M., Noel, Sabrina, Tian, Simon, Waltz, David, Weinstock, Tanya G., Xuan, Fengjuan, Wainwright, Claire E., McColley, Susanna A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483230/ https://www.ncbi.nlm.nih.gov/pubmed/33734030 http://dx.doi.org/10.1164/rccm.202102-0509OC |
Ejemplares similares
-
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
por: Griese, Matthias, et al.
Publicado: (2021) -
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021) -
Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021) -
Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020) -
Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023)